Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: Zidesamtinib Is Associated With CNS Activity and Low Rates of Neurologic AEs in Pretreated ROS1+ NSCLC: With Alexander Drilon, MD
Description: In today’s episode, we had the pleasure of speaking with Alexander Drilon, MD, about the phase 1/2 ARROS-1 trial (NCT05118789) investigating zidesamtinib (NVL-520) in TKI-pretreated patients with advanced ROS1-positive non–small cell lung cancer (NSCLC). Dr Drilon is chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, New York.In our exclusive interview, Dr Drilon discussed the efficacy data and implications of the ARROS-1 trial, highlighted the unique mechanism of action of zidesamtinib, noted the high central nervous system (CNS) response rates and favorable safety profile associated with the agent, and...